Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer

被引:63
作者
Narita, Keishi [1 ]
Chien, Jeremy [1 ]
Mullany, Sally A. [1 ]
Staub, Julie [1 ]
Qian, Xiang [1 ]
Lingle, Wilma L. [1 ]
Shridhar, Viji [1 ]
机构
[1] Mayo Clin, Coll Med, Ctr Canc, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA
关键词
D O I
10.1074/jbc.M611395200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heparan sulfate (HS) glycosaminoglycans are the oligosaccharide chains of heparan sulfate proteoglycans. The sulfation of HS glycosaminoglycan residues is required for its interaction with various heparin-binding growth factors to promote their biological activities to activate their high affinity receptor tyrosine kinases. We have identified HS glycosaminoglycan-6-O-endosulfatase HSulf-1 as a down-regulated gene in ovarian, breast, and several other cancer cell lines. Here we have shown that HSulf-1 inhibits autocrine activation of the EGFR-ERK ( epidermal growth factor receptor-extracellular signal-regulated kinase) pathway induced by serum withdrawal in MDA-MB-468 breast cancer cells. Short hairpin RNA-mediated down-regulation of HSulf-1 in HSulf-1 clonal lines of MDA-MB-468 led to a significant increase in autocrine activation of ERK compared with vector only control. The autocrine signaling was also inhibited with neutralization antibodies against amphiregulin and HB-EGF, the heparin-binding growth factor family of the EGF superfamily. Furthermore, HSulf-1-mediated inhibition of autocrine signaling was associated with reduced cyclin D1 levels, leading to decreased S phase fraction and increased G(2)-M fraction, as well as increased cell death. Finally, evaluation of HSulf-1 expression levels in primary invasive breast tumors by RNA in situ hybridization indicated that HSulf-1 is down-regulated in the majority (60%) of tumors, with a predominant association with lobular histology. These data suggest a potential role of HSulf-1 down-regulation in mammary carcinogenesis.
引用
收藏
页码:14413 / 14420
页数:8
相关论文
共 29 条
[1]  
Agranovich MS, 2005, RUSS J MATH PHYS, V12, P1
[2]   Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome [J].
Arpino, G ;
Bardou, VJ ;
Clark, GM ;
Elledge, RM .
BREAST CANCER RESEARCH, 2004, 6 (03) :R149-R156
[3]   Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients [J].
Bottini, Alberto ;
Generali, Daniele ;
Brizzi, Maria Pia ;
Fox, Stephen B. ;
Bersiga, Alessandro ;
Bonardi, Simone ;
Allevi, Giovanni ;
Aguggini, Sergio ;
Bodini, Giuliana ;
Milani, Manuela ;
Dionisio, Rossana ;
Bernardi, Claudio ;
Montruccoli, Arianna ;
Bruzzi, Paolo ;
Harris, Adrian L. ;
Dogliotti, Luigi ;
Berruti, Alfredo .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3623-3628
[4]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[5]   Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond [J].
Dubey, Sarita ;
Siegfried, Jill M. ;
Traynor, Anne M. .
LANCET ONCOLOGY, 2006, 7 (05) :416-424
[6]  
Evron E, 2001, CANCER RES, V61, P2782
[7]   Novel mechanisms of resistance to endocrine therapy: Genomic and nongenomic considerations [J].
Gururaj, AE ;
Rayala, SK ;
Vadlamudi, RK ;
Kumar, R .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :1001S-1007S
[8]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[9]  
JOHNSON GR, 1994, J BIOL CHEM, V269, P27149
[10]   Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer [J].
Johnston, SRD .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :1061S-1068S